GSK-3 is a Master Regulator of Neural Progenitor Self-Renewal
GSK-3 是神经祖细胞自我更新的主要调节因子
基本信息
- 批准号:8212516
- 负责人:
- 金额:$ 39.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-15 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAllelesBrainBreedingCCI-779Cell CountCell CycleCell ProliferationChemicalsChildDevelopmentDorsalEmbryoEmbryonic Nervous SystemErinaceidaeExhibitsFamily memberFundingGeneticGenetic RecombinationGlycogen Synthase Kinase 3Glycogen Synthase KinasesHippocampus (Brain)HomeostasisInvestigationKnock-in MouseLifeLithiumMammalsMediatingMediator of activation proteinMusMutagenesisNeuronal DifferentiationNeuronsNotch Signaling PathwayPharmaceutical PreparationsPhosphotransferasesPoint MutationPopulationPositioning AttributeProteinsRadialReceptor Protein-Tyrosine KinasesRegulationSignal TransductionSirolimusStem cellsTelencephalonTestingTransplantationWorkcell typecellular imagingchemical geneticsclinical practicedentate gyrusextracellulargranule cellin vivoinhibitor/antagonistnerve stem cellnestin proteinneurogenesisnotch proteinpostnatalprogenitorpublic health relevancerelating to nervous systemresearch studyself-renewal
项目摘要
DESCRIPTION (provided by applicant): In the prior funding period, we demonstrated that conditional elimination of the Glycogen Synthase Kinase-3s (GSK-3s), a and ¿, in the embryonic nervous system results in remarkable dysregulation of neural progenitor homeostasis. This result has important translational significance because of the widespread use of a GSK-3 inhibitor, lithium, in clinical practice. We hypothesize that inactivation of GSK-3s renders progenitors incapable of responding to the extracellular signals that normally regulate conversion of radial progenitors to neurons and intermediate neuronal precursors (INPs). We now propose definitive mouse genetic experiments to assess mechanisms of this GSK-3 regulation (Aims I and II). Further, we will use a chemical genetics approach to determine if reinduction of GSK-3 activity in GSK-3 deficient progenitors will result in enhanced neurogenesis (Aim III). Finally we will ask whether GSK-3 signaling regulates neural progenitors in the adult dentate gyrus (Aim IV). This work will reveal the functional potential and mechanisms of GSK-3 regulation of neural progenitors in mammals. The work will also provide information on previously unrecognized potential effects of lithium a drug commonly used in clinical practice, increasingly in children. Finally our results may suggest new ways to expand neural progenitor populations in the setting of neural transplantation.
PUBLIC HEALTH RELEVANCE: We propose that a specific protein, GSK-3, is a master regulator of neural stem cells. This function of GSK-3 requires investigation because a GSK-3 inhibitor, lithium, is commonly used in clinical practice, increasingly in children. Our results may also suggest new ways to expand neural stem cells in the setting of neural transplantation
描述(申请人提供):在之前的资助期间,我们证明了有条件地消除胚胎神经系统中的糖原合成酶-3s(GSK-3s)α和β会导致神经前体细胞动态平衡的显著失调。这一结果具有重要的翻译意义,因为GSK-3抑制剂锂在临床实践中得到了广泛使用。我们假设,GSK-3S的失活导致祖细胞不能对细胞外信号做出反应,而细胞外信号通常调节放射状祖细胞向神经元和中间神经元前体(INPs)的转换。我们现在建议进行明确的小鼠遗传学实验,以评估这种GSK-3调控的机制(目标I和II)。此外,我们将使用化学遗传学方法来确定在GSK-3缺陷的祖细胞中重新诱导GSK-3活性是否会导致神经发生的增强(目标III)。最后,我们将询问GSK-3信号是否调节成年齿状回的神经前体(目标IV)。这项工作将揭示GSK-3调节哺乳动物神经前体细胞的功能潜力和机制。这项工作还将提供以前未被认识到的锂的潜在影响的信息。锂是一种临床常用药物,越来越多地用于儿童。最后,我们的结果可能会为在神经移植的背景下扩大神经前体种群提供新的方法。
公共卫生相关性:我们提出一种特定的蛋白质,GSK-3,是神经干细胞的主要调节因子。GSK-3的这种功能需要研究,因为一种GSK-3抑制剂锂在临床实践中经常使用,越来越多的儿童使用。我们的结果也可能提出在神经移植的背景下扩增神经干细胞的新方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM D SNIDER其他文献
WILLIAM D SNIDER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM D SNIDER', 18)}}的其他基金
GSK-3B/APC in developmental & regenerative axon growth
GSK-3B/APC 正在开发中
- 批准号:
6887195 - 财政年份:2004
- 资助金额:
$ 39.35万 - 项目类别:
GSK-3B/APC in developmental & regenerative axon growth
GSK-3B/APC 正在开发中
- 批准号:
7234278 - 财政年份:2004
- 资助金额:
$ 39.35万 - 项目类别:
GSK-3B/APC in developmental & regenerative axon growth
GSK-3B/APC 正在开发中
- 批准号:
7069523 - 财政年份:2004
- 资助金额:
$ 39.35万 - 项目类别:
GSK-3 is a Master Regulator of Neural Progenitor Self-Renewal
GSK-3 是神经祖细胞自我更新的主要调节因子
- 批准号:
7783561 - 财政年份:2004
- 资助金额:
$ 39.35万 - 项目类别:
GSK-3 is a Master Regulator of Neural Progenitor Self-Renewal
GSK-3 是神经祖细胞自我更新的主要调节因子
- 批准号:
8604427 - 财政年份:2004
- 资助金额:
$ 39.35万 - 项目类别:
GSK-3B/APC in developmental & regenerative axon growth
GSK-3B/APC 正在开发中
- 批准号:
6948471 - 财政年份:2004
- 资助金额:
$ 39.35万 - 项目类别:
GSK-3B/APC in developmental & regenerative axon growth
GSK-3B/APC 正在开发中
- 批准号:
7418189 - 财政年份:2004
- 资助金额:
$ 39.35万 - 项目类别:
GSK-3 is a Master Regulator of Neural Progenitor Self-Renewal
GSK-3 是神经祖细胞自我更新的主要调节因子
- 批准号:
8017363 - 财政年份:2004
- 资助金额:
$ 39.35万 - 项目类别:
GSK-3 is a Master Regulator of Neural Progenitor Self-Renewal
GSK-3 是神经祖细胞自我更新的主要调节因子
- 批准号:
8414160 - 财政年份:2004
- 资助金额:
$ 39.35万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 39.35万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 39.35万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 39.35万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 39.35万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 39.35万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 39.35万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 39.35万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 39.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 39.35万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 39.35万 - 项目类别: